STK11
STK11 (LKB1) is a master kinase that directly phosphorylates and activates AMPK in response to energy stress. By linking cellular energy status to growth pathways, it acts as a critical tumor suppressor. Germline mutations cause Peutz-Jeghers syndrome, while somatic loss frequently drives aggressive lung cancers.
Key Takeaways
- •STK11 (LKB1) is the master upstream kinase that directly activates AMPK in response to energy stress.
- •It acts as a potent tumor suppressor by linking cellular energy depletion to the inhibition of mTOR-driven growth.
- •Germline mutations in STK11 cause Peutz-Jeghers syndrome, predisposing patients to GI polyps and cancer.
- •Somatic loss in lung cancer drives aggressive, immune-evasive tumors, particularly in KRAS-mutant contexts.
Basic Information
- Gene Symbol
- STK11
- Full Name
- Serine/Threonine Kinase 11
- Also Known As
- LKB1PJS
- Location
- 19p13.3
- Protein Type
- Ser/Thr Kinase
- Protein Family
- CAMK family
Related Isoforms
Pseudokinases essential for STK11 activity and localization.
Scaffold protein that completes the active heterotrimeric complex.
Key SNPs
Associated with variations in fasting glucose and obesity phenotypes in some cohorts.
A known pathogenic variant in the kinase domain linked to Peutz-Jeghers syndrome.
Studied for potential associations with cancer risk and metabolic regulation.
Overview
STK11 (Serine/Threonine Kinase 11), most commonly referred to as LKB1 in the scientific literature, is the apex regulatory kinase of cellular energy homeostasis and cell polarity. It acts as the primary "on switch" for AMPK, the cell’s main energy sensor.
To exert its function, STK11 must bind to two accessory proteins (STRAD and MO25) to form a catalytically active heterotrimeric complex. While STK11 activity is relatively constant, it rapidly phosphorylates AMPK when cellular energy levels drop (high AMP/ATP ratio), because the conformational change in AMP-bound AMPK makes it an ideal substrate for STK11. This links nutrient availability directly to mTOR inhibition, defining STK11 as a critical metabolic tumor suppressor.
Conceptual Model
A simplified mental model for the pathway:
Intentionally simplified; real signaling is shaped by feedback loops, tissue context, and timing.
Core Health Impacts
- • Catabolic activation: Directly activates AMPK to trigger catabolic energy production.
- • mTOR inhibition: Potently inhibits mTOR-driven anabolism and cell growth.
- • Cell structure: Establishes cell polarity and cytoskeletal architecture (via MARKs).
- • Polyp defense: Suppresses the formation of gastrointestinal hamartomatous polyps.
- • Lung cancer defense: Prevents highly aggressive, immune-evasive lung cancer progression.
- • Metformin response: Required for the therapeutic efficacy of metformin.
Protein Domains
N-Terminal Domain
Contains the nuclear localization signal (NLS). Without its partners (STRAD/MO25), STK11 is sequestered and inactive in the nucleus.
Kinase Domain
The central catalytic engine responsible for phosphorylating the activation loop (T-loop) of AMPK and 12 other related kinases.
C-Terminal Regulatory
Contains multiple phosphorylation sites (like Ser431) that regulate protein stability, localization, and response to upstream pathways like PKA.
Upstream Regulators
STRADα / STRADβ Activator
Pseudokinases that bind STK11, forming a heterotrimeric complex necessary for its export from the nucleus and full catalytic activation.
MO25α / MO25β Activator
Scaffolding proteins that bind the STK11-STRAD complex, stabilizing it in an active conformation in the cytoplasm.
PKA and RSK Modulator
Kinases that can phosphorylate STK11 at specific residues (e.g., Ser431) to modulate its activity and subcellular localization.
Energy Stress (Indirectly) Activator
While STK11 activity is largely constitutive, energy stress (high AMP) alters its substrate (AMPK), making AMPK a much better target for STK11.
Downstream Targets
AMPK (PRKAA1/2) Activates
The primary and most famous substrate; phosphorylated at Thr172 by STK11 to activate energy-sensing metabolic cascades.
MARK Family (1-4) Activates
Microtubule affinity-regulating kinases phosphorylated by STK11 to control cell polarity, cytoskeleton dynamics, and migration.
BRSK Family (1/2) Activates
Brain-specific kinases activated by STK11, essential for neuronal polarization and axonogenesis.
SIK Family (1/2) Activates
Salt-inducible kinases regulated by STK11 that modulate cAMP signaling, gluconeogenesis, and lipid metabolism.
NUAK Family (1/2) Activates
Kinases involved in cellular senescence, neuronal development, and cell adhesion, phosphorylated by STK11.
Role in Aging
STK11 is the essential relay switch for almost all metabolic lifespan-extending interventions. It translates environmental energy scarcity into the biochemical signals that engage the cell’s anti-aging maintenance programs.
mTOR Suppression
By phosphorylating AMPK, STK11 provides the necessary braking force against mTORC1. Chronic mTOR activation drives cellular aging; STK11 ensures mTOR is silenced during energy stress.
Autophagy Induction
The STK11-AMPK axis directly phosphorylates ULK1 to initiate autophagy, a critical quality-control process that clears damaged organelles and misfolded proteins (proteostasis) that accumulate with age.
Mitochondrial Biogenesis
STK11 signaling activates PGC-1α (via AMPK), driving the creation of new, healthy mitochondria, combating the age-related decline in oxidative phosphorylation and metabolic flexibility.
Metabolic Flexibility
STK11 allows tissues (especially muscle and liver) to efficiently switch from burning glucose to burning fat during fasting, a capacity that strongly declines in metabolic syndrome and aging.
Stem Cell Maintenance
Loss of STK11/AMPK signaling in adult stem cells (such as hematopoietic stem cells) leads to overproliferation, rapid exhaustion, and premature aging of the stem cell compartment.
Caloric Restriction Mediator
The lifespan-extending effects of caloric restriction and intermittent fasting in many animal models are significantly blunted or abolished if the STK11/AMPK pathway is genetically disabled.
Disorders & Diseases
Peutz-Jeghers Syndrome (PJS)
A rare, autosomal dominant disorder caused by germline mutations in STK11. It is characterized by the development of benign hamartomatous polyps in the gastrointestinal tract and distinctive mucocutaneous hyperpigmentation (dark freckles on the lips and oral mucosa).
Non-Small Cell Lung Cancer (NSCLC)
Somatic mutations in STK11 occur in up to 30% of lung adenocarcinomas. Tumors with concurrent KRAS and STK11 mutations (KL tumors) represent a distinct, highly aggressive clinical subtype that is notoriously resistant to both chemotherapy and immunotherapy.
Cervical Cancer
Somatic STK11 mutations are found in a significant subset of cervical carcinomas, where loss of STK11-mediated cell polarity and mTOR inhibition contributes to malignant progression.
Metabolic Syndrome & T2D
While germline mutations cause PJS, generalized impairment or downregulation of the STK11-AMPK axis due to chronic nutrient excess is a fundamental driver of insulin resistance, hepatic steatosis, and type 2 diabetes.
Interventions
Supplements
Plant alkaloid that activates AMPK; its mechanism relies on an intact STK11/LKB1 axis to phosphorylate AMPK in response to metabolic changes.
Polyphenol that activates SIRT1 and AMPK; the activation of AMPK is STK11-dependent.
Flavonoid known to stimulate the LKB1-AMPK pathway, mimicking mild energy stress.
Lifestyle
Depletes cellular ATP, raising AMP levels, which allows STK11 to efficiently phosphorylate and activate AMPK in muscle.
Lowers systemic energy availability, tonically engaging the STK11-AMPK axis to suppress mTOR and promote longevity pathways.
Creates periods of nutrient deprivation that robustly activate the LKB1-AMPK signaling network to stimulate autophagy.
Medicines
First-line type 2 diabetes drug; mildly inhibits mitochondrial complex I, raising AMP/ATP ratios and absolutely requiring STK11 to activate AMPK.
Can activate AMPK in an STK11-dependent manner by uncoupling oxidative phosphorylation, contributing to its metabolic and anti-cancer effects.
An AMP mimetic used in research that directly binds AMPK, promoting its phosphorylation by STK11 without inhibiting mitochondrial respiration.
Lab Tests & Biomarkers
Genetic Testing
Used to diagnose Peutz-Jeghers syndrome in patients presenting with characteristic hamartomatous polyps and mucocutaneous pigmentation.
Standard NGS panels for lung adenocarcinoma evaluate STK11 and KRAS to determine prognosis and immunotherapy likelihood.
Activity Markers
The direct readout of STK11 catalytic activity; routinely used in research to confirm an intact LKB1-AMPK signaling axis.
Acetyl-CoA carboxylase is the primary target of AMPK; its phosphorylation is a robust surrogate marker for the STK11-AMPK pathway in action.
Clinical Observation
Dark blue to brown macules around the mouth, eyes, nostrils, and buccal mucosa are the classic visible biomarker of germline STK11 mutation.
Hormonal Interactions
Adiponectin Metabolic Activator
An adipokine that stimulates the LKB1-AMPK pathway in liver and muscle, enhancing insulin sensitivity and fatty acid oxidation.
Leptin Metabolic Activator
Can activate AMPK in skeletal muscle (via STK11) to stimulate fatty acid oxidation, while inhibiting it in the hypothalamus to regulate appetite.
Deep Dive
Network Diagrams
STK11 Complex Formation & Substrate Activation
Metabolic and Immune Rewiring by STK11 Loss
Activation Mechanics: The Heterotrimeric Complex
The regulation of STK11 relies on location and complex formation rather than traditional phosphorylation cascades.
Nuclear Sequestration: STK11 monomer contains a strong nuclear localization signal (NLS). Without its partners, it remains trapped in the nucleus where it is catalytically inactive and separated from its primary cytoplasmic targets.
STRAD and MO25 Binding: The pseudokinase STRAD (STE20-related adaptor) binds to STK11, driving it out of the nucleus into the cytoplasm. The scaffolding protein MO25 then binds the complex, stabilizing it. This heterotrimer (STK11-STRAD-MO25) is constitutively active.
Substrate Presentation: Because the STK11 complex is always “on,” metabolic regulation occurs at the level of the substrate. When ATP is plentiful, AMPK is folded tightly. When ATP falls and AMP rises, AMP binds AMPK, causing a conformational shift that exposes Thr172. The ever-present STK11 complex then rapidly phosphorylates and activates it.
Beyond AMPK: The ARK Family and Polarity
While AMPK dominates the metabolic discussion, STK11 actually activates 12 other AMPK-related kinases (ARKs), which are crucial for cellular architecture.
MARKs (Microtubule Affinity-Regulating Kinases): STK11 phosphorylates MARKs to control the cytoskeleton. This establishes apical-basal polarity in epithelial cells—a structural organization that prevents cells from detaching and migrating.
Tumor Suppression via Polarity: The loss of cell polarity is a defining step in the epithelial-mesenchymal transition (EMT) required for cancer metastasis. Loss of STK11 disables the MARK pathway, causing cells to lose their organized structure, contributing to the highly metastatic nature of STK11-null tumors.
Metabolic Vulnerabilities in LKB1-Null Cancers
The loss of STK11 in cancer (particularly lung cancer) completely rewires cellular metabolism, creating distinct vulnerabilities that differ from standard tumors.
Loss of the Brake: Without STK11, tumors cannot sense energy stress. They maintain rampant mTOR signaling and hyper-proliferation even in nutrient-poor environments. This metabolic inflexibility makes them highly dependent on specific nutrient streams.
Glutamine Addiction: STK11-null tumors often heavily rewire to rely on glutamine metabolism to fuel the TCA cycle and support unchecked growth. This makes them hypersensitive to glutaminase (GLS) inhibitors in experimental models.
Immune Evasion (The “Cold” Tumor): STK11 loss strongly suppresses the STING pathway and reduces the production of inflammatory chemokines (like CXCL10). This prevents T-cell infiltration, rendering the tumors “immunologically cold” and profoundly resistant to PD-1/PD-L1 immune checkpoint blockade.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark identification of STK11 (LKB1) as the causal gene for Peutz-Jeghers syndrome, establishing its role as a tumor suppressor.
Biochemical proof that STK11 is the upstream kinase for AMPK and a large family of related kinases regulating polarity and metabolism.
Comprehensive review of how the STK11 pathway regulates structural asymmetry and mitotic progression, linking energy sensing to cell architecture.
Detailed the profound impact of somatic STK11 loss in KRAS-mutant non-small cell lung cancer, including immune evasion and metabolic rewiring.
While STK11 is the primary AMPK kinase for energy stress (like metformin), other pathways exist, highlighting network complexity.